The pharma industry is no stranger to standards. Pharmaceutical companies have entire teams devoted to ensuring that all data and content is collected, created, managed, retained, and retired according to regulatory requirements.
Using component-based structured content authoring and having a robust reuse strategy is the only way to produce pharma content at scale. It’s how you produce accurate content efficiently across the enterprise. It’s how you deliver the right content to the right place at the right time, such as when you
We can no longer afford the costs of traditional, document-based content management in the pharmaceutical industry. We need pharma companies to prioritize content reuse and automation rather than manual, error-prone legacy processes.
In The Unique Challenges of Pharma Content, we discuss challenges faced by pharmaceutical companies in the creation and management of content.
Most content challenges are ubiquitous, present in every vertical. Processes that don’t scale. Too much content to manage and yet the exact right content never seems to be at hand. Authors must copy and paste and (inevitably) tweak content, wasting time and increasing risk. The challenges of time, cost, and
For centuries, humans have shared information through documents. We’ve used digital files, printed paper, illuminated manuscripts, parchment scrolls, and clay tablets. Regardless of form factor, a document has traditionally been created as a single monolithic entity, authored in the same format in which it was intended to be consumed.
A reuse map is a blueprint for planned content reuse. Planned content reuse means that you identify ahead of time exactly which pieces of content will be reused in a specific output.
EU Medical Device Regulation (2017/745) and In Vitro Diagnostic Regulation (2017/746) went into effect in May 2021, after about a year’s delay due to COVID-19. Medical device manufacturers have known about the new regulations for years and have been working to meet these new, more stringent standards.